

Martin Ogletree, Ph.D. Advisor

Former Distinguished Research Fellow and Director of Thrombosis Research, Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb

Dr. Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb. At Merck he also led target identification and validation for the cardiovascular franchise.

As Distinguished Research Fellow and Director of thrombosis research in Metabolic and Cardiovascular Drug Discovery at Bristol-Myers Squibb, he led thrombosis biology research as well as early clinical development teams, including the teams that advanced ELIQUIS (apixaban) in drug discovery, preclinical development and early clinical development.

He participated in the partnering, registration, research, and strategic positioning of PLAVIX (clopidogrel) and led the evaluation and integration of coagulation assets, including COUMADIN and the factor Xa inhibitor program, upon acquisition of DuPont Pharmaceuticals.

Prior to joining Merck, he worked as Director of Development at Cumberland Pharmaceuticals in Nashville where he prepared an IND for ACETADOTE (acetylcysteine for injection) and contributed to an sNDA for its use in acute liver failure. At Cumberland he also led work to repurpose the thromboxane receptor antagonist, HEPATOREN (ifetroban), including manufacture of drug substance for clinical trials, planning clinical development, and preparing the IND and other regulatory documents.

Dr. Ogletree earned a B.A. in biology from Swarthmore College and a Ph.D. in Physiology from Thomas Jefferson University. He received post-doctoral training in pulmonary medicine and pharmacology at Vanderbilt University School of Medicine. He has published more than 100 articles in peer-reviewed journals. He currently serves as Adjunct Professor of Pharmacology at Vanderbilt University and on the Temple University Health System Board's Quality and Patient Safety Committee and on the Jeanes Hospital Board as chair of the Professional Affairs Committee.